NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
